Plasmodium Vivax Diagnostic Test for Hypnozoite Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for Plasmodium vivax infections are inadequate in detecting dormant liver-stage hypnozoites and distinguishing between recent and chronic infections, as they primarily focus on blood-stage antigens and lack comprehensive characterization of the parasite's life cycle dynamics within the body.

Innovation Solution

A diagnostic system and method that utilizes antibody measurements to determine the timing of P. vivax infections by identifying specific proteins such as PVX_099980, PVX_112670, and RBP2b, which can indicate the presence of dormant liver-stage hypnozoites and differentiate between recent and chronic infections, employing a combination of short-lived and long-lived antibodies measured at multiple time points to estimate the elapsed time since infection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current diagnostic methods focus on blood-stage antigens, then detection of active blood infections is achieved, but dormant liver-stage hypnozoites remain undetected

Engineering Contradiction:

Improvedetection accuracyVSAvoiddetection of dormant hypnozoites

Core Design Contradiction:

ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The diagnostic approach segments the malaria infection detection into distinct phases: blood-stage detection (current infection) and liver-stage detection (dormant hypnozoites). By measuring multiple antibody isotypes (IgG, IgA, IgM) and their ratios, the system can distinguish between recent blood infections and dormant liver infections, addressing both detection needs simultaneously

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses antibody isotype ratios as intermediary markers to indirectly detect dormant hypnozoites. Since direct detection of liver-stage parasites is difficult, the system measures antibody responses (IgG/IgA/IgM ratios) that serve as mediators to infer the presence and timing of infections, including dormant liver-stage infections

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If diagnostic tests measure antibody levels at a single time point, then testing simplicity is maintained, but inability to distinguish recent from chronic infections occurs

Engineering Contradiction:

Improvetesting simplicityVSAvoidinfection timing information

Core Design Contradiction:

Ease of operationVSLoss of information

Solution Approach 1:

The system performs preliminary measurements of multiple antibody isotypes (IgG, IgA, IgM) and their ratios at the time of testing. By establishing this baseline antibody profile, the system can later distinguish between recent and chronic infections based on the temporal pattern of antibody responses, providing infection timing information without complicating the testing procedure

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The diagnostic method dynamically evaluates antibody isotype ratios over time to determine infection timing. By analyzing how antibody levels change and decay at different time points, the system can distinguish between recent infections (higher IgM, lower IgG) and chronic infections (higher IgG, lower IgM), providing temporal information while maintaining operational simplicity

Inventive Principle:

Principle #15Dynamics

3Measurement precision

If comprehensive characterization of parasite life cycle dynamics is implemented, then complete infection monitoring is achieved, but device and test complexity increases

Engineering Contradiction:

Improveinfection characterization accuracyVSAvoiddiagnostic system complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent applies local quality by focusing measurement on specific, informative antibody isotypes (IgG, IgA, IgM) and their ratios rather than measuring all possible markers. This targeted approach provides sufficient characterization of infection dynamics and timing while avoiding the complexity of comprehensive multi-marker panels

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The antibody ratio measurement system serves multiple functions simultaneously: it detects current blood infections, identifies dormant liver-stage hypnozoites, determines infection timing (recent vs. chronic), and characterizes infection dynamics. This multi-functionality achieves comprehensive infection characterization without proportionally increasing test complexity

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS12259387B2System, method, apparatus and diagnostic test for plasmodium vivax

Publication Date: 2025.03.25 THE WALTER AND ELIZA HALL INSTITUTE OF MEDECAL RESEARCH

AI summary

A system, method, apparatus and diagnostic test for Plasmodium vivax, to determine a likelihood of a specific timing of infection by P. vivax in a subject, and hence identify individuals with a high probability of being infected with otherwise undetectable liver-stage hypnozoites. The system, method, apparatus and diagnostic test relate to the identification of hypnozoites (“dormant” liver-stages), or at least of the likelihood of the subject being so infected. Optionally and preferably, the specific timing relates to recent infections, for example within the last 9 months.